Prelude Capital Management, LLC Adaptimmune Therapeutics PLC Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $22,662 - $38,023	25,181 New	25,181 $23,000
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $3,151 - $8,397	-2,204 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$3.23 - $5.41 $4,473 - $7,492	1,385 Added 169.11%	2,204 $9,000
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $355 - $593	-98 Reduced 10.69%	819 $4,000
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $194,925 - $734,082	-51,842 Reduced 98.26%	917 $5,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $1,149 - $1,884	-139 Reduced 0.26%	52,759 $715,000
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $487,614 - $642,977	-46,796 Reduced 46.94%	52,898 $628,000
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $289,971 - $472,121	40,841 Added 69.39%	99,694 $1.12 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $95,483 - $124,929	14,294 Added 32.08%	58,853 $393,000
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $219,675 - $397,911	44,559	44,559 $365,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.